Clinical Trial Update: SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for SDTM001 Injection as adjuvant therapy in patients with Non-Small Cell Lung Cancer after radical surgical resection. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SDTM001 Injection (SDTM001)

Snippet

Sponsor: Cytocraft Biopharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING